Experimental and theoretical investigations on the keto–enol tautomerism of 4-substituted 3-[1-methylpyrrol-2-yl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives
-
Add time:07/26/2019 Source:sciencedirect.com
Keto–enol tautomerism is a key phenomenon which determines the pharmacological activity of compounds possessing the carbonyl group. In the present study we use X-ray analysis, IR spectroscopy as well as quantum chemical calculation to address the keto–enol tautomerism of 4-substituted 3-[1-methylpyrrol-2-yl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives with antimicrobial activity. In the gas phase and in the crystalline state all the investigated molecules exist in the keto form while in the chloroform solution a small amount of the enol form in the equilibrium with the keto form is observed. The results of the calculations are in good agreement with experimental data obtained from X-ray analysis and IR spectroscopy in KBr but do not confirm the shift of the tautomeric equilibrium into the enol form in a chloroform solution.
We also recommend Trading Suppliers and Manufacturers of 1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine (cas 109835-15-6). Pls Click Website Link as below: cas 109835-15-6 suppliers
Prev:Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-YL)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-YL) pyridine by human monoamine oxidases A and B
Next:Concise synthesis of 2-methoxyestradiol from 17β-estradiol through the C(sp2)-H hydroxylation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-YL)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-YL) pyridine by human monoamine oxidases A and B07/25/2019
- Halogen bonding in crystal structure of 1-methylpyrrol-2-yl trichloromethyl ketone07/24/2019
- Uncatalyzed addition of indoles and N-methylpyrrole to 3-formylchromones: synthesis and some reactions of (chromon-3-yl)bis(indol-3-yl)methanes and E-2-hydroxy-3-(1-methylpyrrol-2-ylmethylene)chroman-4-ones07/23/2019


